DK1987178T3 - Fremgangsmåde til konstruktion og screening af peptidstrukturbiblioteker - Google Patents

Fremgangsmåde til konstruktion og screening af peptidstrukturbiblioteker Download PDF

Info

Publication number
DK1987178T3
DK1987178T3 DK07750247.4T DK07750247T DK1987178T3 DK 1987178 T3 DK1987178 T3 DK 1987178T3 DK 07750247 T DK07750247 T DK 07750247T DK 1987178 T3 DK1987178 T3 DK 1987178T3
Authority
DK
Denmark
Prior art keywords
sequences
peptide
protein
amino acid
peptides
Prior art date
Application number
DK07750247.4T
Other languages
English (en)
Inventor
Paul Michael Watt
Roland Dunbrack
Original Assignee
Phylogica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006900864A external-priority patent/AU2006900864A0/en
Application filed by Phylogica Ltd filed Critical Phylogica Ltd
Application granted granted Critical
Publication of DK1987178T3 publication Critical patent/DK1987178T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1072—Differential gene expression library synthesis, e.g. subtracted libraries, differential screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6818—Sequencing of polypeptides
    • G01N33/6824—Sequencing of polypeptides involving N-terminal degradation, e.g. Edman degradation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/20—Screening of libraries
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Library & Information Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Computing Systems (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)

Claims (12)

1. Fremgangsmåde til frembringelse af et peptidbibliotek omfattende forskelligartede proteinstrukturer, hvilken fremgangsmåde omfatter: (i) opnåelse af en flerhed af aminosyresekvenser af forskelligartede proteinstrukturer fra bioinformatikkildedata og identifikation af fragmenter af proteiner, der datamæssigt er forudset til uafhængigt at danne sekundære strukturer og/eller enheder af sekundære strukturer og/eller foldninger, når de isoleres fra de flankerende sekvenser i oprindelsesproteinet, som bestemt ifølge tre kriterier for kompakthed, ikke-polært indesluttet overfladeareal og grad af uafhængighed ifølge scoringsfunktionen:
hvor: Z, H, og I er henholdsvis et fragments kompakthed, hydrofobicitet og grad af isolering, hvor: Z er det overfladeareal af fragmentet, der er tilgængeligt for opløsningsmiddel, divideret med et minimalt overfladeareal af fragmentet, der er overfladearealet af en kugle med et volumen svarende til fragmentet; H er en fraktion af indesluttet, ikke-polært areal i det fulde ikke-polære areal; I er en fraktion af overfladearealet, som er tilgængeligt for ikke-polært opløsningsmiddel, og som oprindeligt var indesluttet i det indre af et protein men eksponeret for opløsningsmiddel efter skæring i fragmentets totale overfladeareal, der er tilgængeligt for opløsningsmiddel; avg betegner et aritmetisk gennemsnit af Z1, Η1, I1, Z2, H2 og I2, hvor 1 med hævet skrift definerer Z, Η, I beregnet efter fragmentstørrelse, og hvor 2 med hævet skrift definerer Z, Η, I beregnet som en funktion af fraktionen af fragmentstørrelsen i forhold til det fulde protein; og Dev betegner en standardafvigelse af Z1, Η1, I1, Z2, H2 og I2, hvor 1 med hævet skrift definerer Z, Η, I beregnet efter fragmentstørrelse, og hvor 2 med hævet skrift definerer Z, Η, I beregnet som en funktion af fraktionen af fragmentstørrelsen i forhold til det fulde protein; (ii) frembringelse af peptider med aminosyresekvenserne opnået i (i) og (iii) visning af peptiderne i (ii), således at peptiderne danner sekundære strukturer og/eller enheder af sekundære strukturer og/eller foldninger.
2. Fremgangsmåde ifølge krav 1, hvilken fremgangsmåde endvidere omfatter identifikation af redundante sekvenser og fjernelse eller deletering af redundante sekvenser for derved at efterlade en ikke-redundant eller normaliseret flerhed af aminosyresekvenser.
3. Fremgangsmåde ifølge krav 1 eller 2, hvilken fremgangsmåde endvidere omfatter identifikation af sekvenser, der er relateret til den opnåede flerhed af aminosyresekvenser, og tilføjelse af disse sekvenser til flerheden af aminosyresekvenser.
4. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 3, hvilken fremgangsmåde endvidere omfatter mutation af peptider, der forudses at danne en sekundær struktur eller enhed af sekundære strukturer eller en foldning eller mutation af nukleinsyrer, der koder for peptiderne.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvilken fremgangsmåde endvidere omfatter udførelse af kombinationer, der er udvalgt fra: (I) (a) mutation af peptider og (b) identifikation af redundante sekvenser og fjernelse eller deletering af redundante sekvenser for derved at efterlade en ikke-redundant eller normaliseret flerhed af aminosyresekvenser; (ii) (a) identifikation af sekvenser, der er relateret til den opnåede flerhed af aminosyresekvenser, og tilføjelse af disse sekvenser til flerheden af aminosyresekvenser og (b) identifikation af redundante sekvenser og fjernelse eller deletering af redundante sekvenser for derved at efterlade en ikke-redundant eller normaliseret flerhed af aminosyresekvenser; og (iii) (a) mutation af peptider og (b) identifikation af redundante sekvenser og fjernelse eller deletering af redundante sekvenser for derved at efterlade en ikke-redundant eller normaliseret flerhed af aminosyresekvenser og (c) identifikation af sekvenser, der er relateret til den opnåede flerhed af aminosyresekvenser, og tilføjelse af disse sekvenser til flerheden af aminosyresekvenser.
6. Fremgangsmåde ifølge krav 5, hvilken fremgangsmåde omfatter gentagelser af en hvilken som helst af (i) og/eller (ii) og/eller (iii) i en hvilken som helst rækkefølge for derved at frembringe et ikke-redundant og dog yderst forskelligartet datasæt.
7. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 6, hvor peptiderne frembringes ved hjælp af syntetiske eller rekombinante midler.
8. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 7, hvor peptiderne vises som grupper på en fast overflade eller en flerhed af faste overflader eller udtrykt på overfladen af en phag eller en celle ved ribosomvisning eller ved visning in vitro eller udtrykt i en celle eller en flerhed af celler.
9. Fremgangsmåde ifølge krav 2 eller 5, hvor den ikke-redundante flerhed indbefatter relaterede strukturer, der adskiller sig ved deres evne til at foldes autonomt eller ved deres ligand-bindingsaffiniteter og/eller associerings-/dissocieringskonstanter for en ligand eller ved deres kemiske modifikationer.
10. Fremgangsmåde til fremstilling af et peptidbibliotek omfattende forskelligartede proteinstrukturer, hvilken fremgangsmåde omfatter: (i) identifikation af en flerhed af aminosyresekvenser og forskelligartede proteinstrukturer fra bioinformatikkildedata og identifikation af fragmenter af proteiner, der datamæssigt er forudset til uafhængigt at danne sekundære strukturer og/eller enheder af sekundære strukturer og/eller foldninger, når de isoleres fra de flankerende sekvenser i oprindelsesproteinet, bestemt ud fra tre kriterier for kompakthed, non-polært indesluttet overfladeareal og grad af uafhængighed ifølge scoringsfunktionen:
Z, H, og I henholdsvis er et fragments kompakthed, hydrofobicitet og grad af isolering, hvor: Z er det overfladeareal af fragmentet, der er tilgængeligt for opløsningsmiddel, divideret med et minimalt overfladeareal af fragmentet, der er overfladearealet af en kugle med et volumen svarende til fragmentet; H er en fraktion af indesluttet, ikke-polært areal i det fulde ikke-polære areal; I er en fraktion af overfladearealet, som er tilgængeligt for ikke-polært opløsningsmiddel, og som oprindeligt var indesluttet i det indre af et protein men eksponeret for opløsningsmiddel efter skæring i fragmentets totale overfladeareal, der er tilgængeligt for opløsningsmiddel; avg betegner et aritmetisk gennemsnit af Z1, Η1, I1, Z2, H2 og I2, hvor 1 med hævet skrift definerer Z, Η, I beregnet efter fragmentstørrelse, og hvor 2 med hævet skrift definerer Z, Η, I beregnet som en funktion af fraktionen af fragmentstørrelsen i forhold til det fulde protein; og Dev betegner en standardafvigelse af Z1, Η1, I1, Z2, H2 og I2, hvor 1 med hævet skrift definerer Z, Η, I beregnet efter fragmentstørrelse, og hvor 2 med hævet skrift definerer Z, Η, I beregnet som en funktion af fraktionen af fragmentstørrelsen i forhold til det fulde protein; (ii) størrelsesudvælgelse af disse sekvenser i (i) for derved at identificere et undersæt af sekvenser med den gennemsnitlige længde af en uafhængig proteinfoldning; (iii) identifikation af redundante sekvenser fra sekvenserne udvalgt i (ii) og fjernelse eller deletering af redundante sekvenser for derved at efterlade en ikke-redundant flerhed af aminosyresekvenser; (iv) frembringelse af peptider fra den ikke-redundante flerhed af aminosyresekvenser i (iii); og (v) visning af peptiderne i (iv), således at peptiderne danner sekundære strukturer og/eller enheder af sekundære strukturer og/eller foldninger.
11. Fremgangsmåde ifølge krav 10, hvilken fremgangsmåde omfatter: (i) identifikation af en flerhed af aminosyresekvenser, der er i stand til at foldes uafhængigt af andre dele af proteinerne, hvori de er indeholdt i deres native kontekster; (ii) størrelsesudvælgelse af disse sekvenser i (i) for derved at identificere et undersæt af sekvenser med den gennemsnitlige længde af en uafhængig proteinfoldning; (iii) identifikation af redundante sekvenser fra sekvenserne, der er udvalgt i (ii) , og fjernelse eller deletering af redundante sekvenser for derved at efterlade en ikke-redundant flerhed af aminosyresekvenser; (iv) frembringelse af en forskelligartet sekvenspulje ved en fremgangsmåde omfattende identifikation af sekvenser, der er relateret til den ikke-redundante flerhed af aminosyresekvenser i (iii), og tilføjelse af disse sekvenser til den ikke-redundante flerhed af aminosyresekvenser i (iii) ; (v) frembringelse af peptider fra den forskelligartede pulje af sekvenser i (iv) ; og (vi) visning af peptiderne i (v), således at peptiderne danner sekundære strukturer og/eller enheder af sekundære strukturer og/eller foldninger.
12. Screeningsfremgangsmåde omfattende: (i) udførelse af en fremgangsmåde ifølge et hvilket som helst af kravene 1 til 11 for derved at frembringe et peptidbibliotek; og (ii) screening af det således frembragte peptidbibliotek for derved at identificere et peptid.
DK07750247.4T 2006-02-20 2007-02-07 Fremgangsmåde til konstruktion og screening af peptidstrukturbiblioteker DK1987178T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2006900864A AU2006900864A0 (en) 2006-02-20 Methods of constructing and screening peptide libraries
PCT/US2007/003393 WO2007097923A2 (en) 2006-02-20 2007-02-07 Method of constructing and screening libraries of peptide structures

Publications (1)

Publication Number Publication Date
DK1987178T3 true DK1987178T3 (da) 2015-04-20

Family

ID=38437853

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07750247.4T DK1987178T3 (da) 2006-02-20 2007-02-07 Fremgangsmåde til konstruktion og screening af peptidstrukturbiblioteker

Country Status (7)

Country Link
US (3) US8575070B2 (da)
EP (1) EP1987178B1 (da)
JP (2) JP5576610B2 (da)
AU (1) AU2007218045B2 (da)
CA (2) CA2638912A1 (da)
DK (1) DK1987178T3 (da)
WO (1) WO2007097923A2 (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270969B2 (en) * 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
US9575070B2 (en) * 2001-12-04 2017-02-21 Wayne State University Neoepitope detection of disease using protein arrays
PL1759001T3 (pl) 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
CA2568644C (en) * 2004-06-03 2015-11-24 Phylogica Limited Peptide modulators of cellular phenotype and bi-nucleic acid fragment library
DK1987178T3 (da) * 2006-02-20 2015-04-20 Phylogica Ltd Fremgangsmåde til konstruktion og screening af peptidstrukturbiblioteker
JP2010515463A (ja) * 2007-01-12 2010-05-13 シー レーン バイオテクノロジーズ， エルエルシー 配座的に束縛されたポリペプチド配列のコンビナトリアルライブラリー
DE102007030904A1 (de) * 2007-07-03 2009-02-05 Pharis Biotec Gmbh Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung
HUE025636T2 (en) * 2007-07-27 2016-04-28 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
KR101744514B1 (ko) 2009-03-18 2017-06-08 온코세라피 사이언스 가부시키가이샤 Ｎｅｉｌ3 펩티드 및 이를 포함하는 백신
CA2769444A1 (en) 2009-05-19 2010-11-25 Aic Blab Company Composite current collector and methods therefor
WO2010135431A2 (en) * 2009-05-19 2010-11-25 The Regents Of The University Of California Compositions, devices, and methods related to prostate-specific membrane antigen
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
EP3351641A1 (en) 2011-04-08 2018-07-25 Tufts Medical Center, Inc. Pepducin design and use
KR101323846B1 (ko) * 2011-04-08 2013-10-31 광주과학기술원 타겟 친화도가 유지되고 안정성이 개선된 ｄ－앱타이드
WO2012158169A1 (en) * 2011-05-18 2012-11-22 Affinergy, Inc. Methods and compositions for tissue repair
WO2013021384A1 (en) * 2011-08-11 2013-02-14 Yeda Research And Development Co. Ltd Compositions and methods for modulating apoptosis
US9944675B2 (en) 2011-09-01 2018-04-17 University Of Southern California Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
WO2013116903A1 (en) 2012-02-10 2013-08-15 Phylogica Limited Methods for the characterisation of interaction sites on target proteins
SMT201800368T1 (it) * 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2014010231A1 (en) * 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Kif20a epitope peptides for th1 cells and vaccines containing the same
TWI658049B (zh) * 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
WO2015098963A1 (ja) * 2013-12-26 2015-07-02 東亞合成株式会社 カルレティキュリンの発現促進方法および該方法に用いられる合成ペプチド
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
TWI565712B (zh) * 2014-10-20 2017-01-11 福又達生物科技股份有限公司 增進神經元生長的胜肽及其應用
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
EP3247407A4 (en) 2015-01-21 2018-08-22 Inhibrx LP Non-immunogenic single domain antibodies
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
JP6807606B2 (ja) 2015-07-16 2021-01-06 インヒブルクス インコーポレイテッド 多価及び多重特異性ｄｒ５結合融合タンパク質
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
WO2017078761A2 (en) * 2015-11-06 2017-05-11 Evorx Technologies, Inc. Her-2-specific cyclized supr peptides
CA3005070A1 (en) * 2015-11-11 2017-05-18 Serimmune Inc. Methods and compositions for assessing antibody specificities
ES2984663T3 (es) 2015-11-13 2024-10-30 Oasis Pharmaceuticals Llc Moduladores del receptor 2 activados por proteasa
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
ITUA20161610A1 (it) * 2016-03-14 2017-09-14 Angela Anna Messina Composto peptidico farmacologicamente attivo, procedimento per la sua preparazione e suo uso.
KR20180125979A (ko) 2016-04-01 2018-11-26 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
EP3694545A4 (en) 2017-10-11 2021-12-01 Board Of Regents, The University Of Texas System HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM
US11976128B2 (en) 2018-03-23 2024-05-07 Board Of Regents, The University Of Texas System Human PD-L2 antibodies and methods of use therefor
EP3768723A4 (en) 2018-03-23 2021-12-29 Board of Regents, The University of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
EP4501355A3 (en) 2018-03-23 2025-04-30 Board Of Regents, The University Of Texas System Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
BR112021000455A2 (pt) * 2018-07-12 2021-04-06 Hexamer Therapeutics, Inc. Suporte de peptídeo de automontagem
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
GB201816440D0 (en) 2018-10-09 2018-11-28 Phoremost Ltd Nucleic acid libraries, peptide libraries and uses thereof
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US20230055519A1 (en) * 2020-01-16 2023-02-23 The Translational Genomics Research Institute Methods of identifying synthetic molecular binding agents
US12611447B2 (en) 2020-09-04 2026-04-28 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
AU2022218782B2 (en) 2021-02-12 2026-06-25 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2022192450A2 (en) * 2021-03-10 2022-09-15 The Board Of Regents Of The University Of Oklahoma Self-assembling peptides, nanofibers, and methods of use
CN112995220A (zh) * 2021-05-06 2021-06-18 广东电网有限责任公司佛山供电局 一种用于计算机网络安全数据保密系统
WO2023192976A1 (en) 2022-04-01 2023-10-05 Board Of Regents, The University Of Texas System Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
CN115894624B (zh) * 2022-12-29 2023-12-08 吉林大学 一种以多肽为配体的金纳米簇及盐酸金霉素的检测方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449853T1 (de) * 1990-02-01 2009-12-15 Siemens Healthcare Diagnostics HERSTELLUNG UND VERWENDUNG VON GENBANKEN MENSCHLICHER ANTIKÖRPER(ßHUMAN-ANTIKÖRPER- BIBLIOTHEKENß)
DE69129154T2 (de) * 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
WO1994006920A1 (en) * 1992-09-22 1994-03-31 Medical Research Council Recombinant viruses displaying a nonviral polypeptide on their external surface
US5834247A (en) * 1992-12-09 1998-11-10 New England Biolabs, Inc. Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein
US6521425B2 (en) * 1997-03-05 2003-02-18 New England Biolabs, Inc. Screening and use of reagents which block or activate intein splicing utilizing natural or homologous exteins
US5470953A (en) 1993-12-23 1995-11-28 Icos Corporation Human β2 integrin α subunit
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
CA2211131A1 (en) 1995-01-23 1996-08-01 Microcide Pharmaceuticals, Inc. Screening for modulators of biomolecules
US5883074A (en) 1995-02-08 1999-03-16 Microcide Pharmaceuticals, Inc. Potentiators of antibacterial agents
AU5939996A (en) 1995-06-07 1996-12-30 Microcide Pharmaceuticals, Inc. Methods for evaluation of antimicrobial targets
US20030215798A1 (en) * 1997-06-16 2003-11-20 Diversa Corporation High throughput fluorescence-based screening for novel enzymes
US6238884B1 (en) * 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US5783431A (en) * 1996-04-24 1998-07-21 Chromaxome Corporation Methods for generating and screening novel metabolic pathways
US5763239A (en) * 1996-06-18 1998-06-09 Diversa Corporation Production and use of normalized DNA libraries
US5955275A (en) * 1997-02-14 1999-09-21 Arcaris, Inc. Methods for identifying nucleic acid sequences encoding agents that affect cellular phenotypes
AU4867097A (en) 1996-10-10 1998-05-05 Institut Pasteur Transgenic or mutated animal as model for a neuron deficit
US5846722A (en) 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
CA2270394A1 (en) 1996-10-31 1998-05-07 Novalon Pharmaceutical Corporation Identification of drugs using complementary combinatorial libraries
GB9703406D0 (en) * 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
US6720413B1 (en) * 1997-03-04 2004-04-13 Musc Foundation For Research Development Methods and compositions for diagnosis and treatment of cancer
US6083715A (en) * 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6583275B1 (en) * 1997-07-02 2003-06-24 Genome Therapeutics Corporation Nucleic acid sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics
US20030191301A1 (en) * 1997-12-29 2003-10-09 Juan F. Medrano Cloning of a high growth gene
EP1053347B1 (en) 1998-01-09 2007-02-28 Phylogica Limited Peptide detection method
US6436694B1 (en) * 1998-01-09 2002-08-20 Cubist Pharmaceuticals, Inc. Regulable gene expression in gram-positive bacteria
US6475726B1 (en) * 1998-01-09 2002-11-05 Cubist Pharmaceuticals, Inc. Method for identifying validated target and assay combinations for drug development
US6846625B1 (en) * 1998-01-09 2005-01-25 Cubist Pharmaceuticals, Inc. Method for identifying validated target and assay combination for drug development
CA2319828A1 (en) 1998-01-29 1999-08-05 Miller, Samuel High density arrays for proteome analysis and methods and compositions therefor
US6316223B1 (en) * 1998-03-30 2001-11-13 Rigel Pharmaceuticals, Inc. Mammalian protein interaction cloning system
US6225530B1 (en) * 1998-04-15 2001-05-01 The Salk Institute For Biological Studies Flowering locus T (FT) and genetically modified plants having modulated flower development
US6190908B1 (en) * 1998-08-12 2001-02-20 The Scripps Research Institute Modulation of polypeptide display on modified filamentous phage
US7315786B2 (en) * 1998-10-16 2008-01-01 Xencor Protein design automation for protein libraries
US6720139B1 (en) * 1999-01-27 2004-04-13 Elitra Pharmaceuticals, Inc. Genes identified as required for proliferation in Escherichia coli
US7270969B2 (en) * 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
ES2402878T3 (es) 1999-05-05 2013-05-10 Phylogica Limited Aislamiento de moduladores biológicos a partir de colecciones de fragmentos génicos biodiversos
US7803765B2 (en) * 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
WO2000076308A1 (en) 1999-06-14 2000-12-21 Exelixis, Inc. Animal models and methods for analysis of lipid metabolism and screening of pharmaceutical and pesticidal agents that modulate lipid metabolism
JP2003517816A (ja) 1999-08-11 2003-06-03 イオス バイオテクノロジー， インコーポレイテッド 新脈管形成の診断の新規方法、新脈管形成調節因子についてのスクリーニングの組成物および方法
US6560542B1 (en) * 2000-01-24 2003-05-06 The Cielo Institute Algorithmic design of peptides for binding and/or modulation of the functions of receptors and/or other proteins
US6865492B2 (en) * 2000-01-24 2005-03-08 The Cielo Institute, Inc. Algorithmic design of peptides for binding and/or modulation of the functions of receptors and/or other proteins
US20020150906A1 (en) * 2000-07-12 2002-10-17 California Institute Of Technology Method for determining three-dimensional protein structure from primary protein sequence
US6962798B2 (en) * 2000-12-21 2005-11-08 Board Of Regents, The University Of Texas System Methods and compositions relating to a cardiac-specific nuclear regulatory factor
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
EP1277835A1 (en) 2001-07-19 2003-01-22 Libragen Methods of creating genetic diversity
US7413870B2 (en) 2001-08-01 2008-08-19 Rigel Pharmaceuticals, Incorporated SAK: modulation of cellular proliferation for treatment of cancer
WO2003014325A2 (en) * 2001-08-10 2003-02-20 Xencor Protein design automation for protein libraries
WO2003040168A2 (en) 2001-11-06 2003-05-15 Enanta Pharmaceuticals, Inc. Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
AU2002351175A1 (en) 2001-11-26 2003-06-10 Bristol-Myers Squibb Company Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
AU2003209879A1 (en) 2002-03-08 2003-09-22 Universite De Montreal Vpr modulators and uses thereof
AU2005274616A1 (en) * 2004-08-20 2006-02-23 Phylogica Limited Peptide inhibitors of c-Jun dimerization and uses thereof
DK1987178T3 (da) * 2006-02-20 2015-04-20 Phylogica Ltd Fremgangsmåde til konstruktion og screening af peptidstrukturbiblioteker

Also Published As

Publication number Publication date
US8575070B2 (en) 2013-11-05
EP1987178A2 (en) 2008-11-05
AU2007218045A1 (en) 2007-08-30
JP2010517930A (ja) 2010-05-27
CA2638912A1 (en) 2007-08-30
US9567373B2 (en) 2017-02-14
US20080081768A1 (en) 2008-04-03
WO2007097923A3 (en) 2008-10-30
JP2014205669A (ja) 2014-10-30
AU2007218045B2 (en) 2011-11-10
US20140128268A1 (en) 2014-05-08
WO2007097923A2 (en) 2007-08-30
US20170183374A1 (en) 2017-06-29
EP1987178B1 (en) 2015-03-25
EP1987178A4 (en) 2010-06-02
JP5576610B2 (ja) 2014-08-20
CA2950465A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
JP5576610B2 (ja) ペプチド構造のライブラリーの構築およびスクリーニング方法
Callahan et al. Mirror-image ligand discovery enabled by single-shot fast-flow synthesis of D-proteins
EP2198022B1 (en) Designed armadillo repeat proteins
Koehbach et al. MALDI TOF/TOF-based approach for the identification of D-amino acids in biologically active peptides and proteins
Ye et al. Binary combinatorial scanning reveals potent poly-alanine-substituted inhibitors of protein-protein interactions
EP1793841B1 (en) Peptide inhibitors of c-jun dimerization and uses thereof
WO1998023781A1 (en) Ligand detection system and methods of use thereof
Ma et al. Chemical synthesis of proteins with Base‐Labile posttranslational modifications enabled by a Boc‐SPPS based General strategy towards peptide C‐Terminal salicylaldehyde esters
Nissen et al. Targeting protein-protein interactions with trimeric ligands: high affinity inhibitors of the MAGUK protein family
Minakhin et al. Mapping the molecular interface between the σ70 subunit of E. coli RNA polymerase and T4 AsiA
Dalby et al. Evolution of binding affinity in a WW domain probed by phage display
Christ et al. Identification of protein domains by shotgun proteolysis
EP1758924B1 (en) Peptides antagonists for inhibiting heat shock protein (hsp 16.3) of mycobacterium tuberculosis
Vince et al. Synthesis of Scyllatoxin‐Based BH3 Domain Mimetics With Diverse Patterns of Native Disulfide Bonds
US7569537B2 (en) Peptide antagonists for inhibiting heat shock protein (Hsp 16.3) of Mycobacterium tuberculosis
Lee Experimental and Computational Advancements in Peptidomimetic Ligand Discovery
Fothergill-Gilmore Peptide sequence determination
JP2007143423A (ja) 標的分子−ポリペプチド間相互作用解析方法
Dente et al. Use of random peptide phage-displayed libraries for studying protein phosphorylation and phosphotyrosine-dependent protein-protein interactions
Hard Sequence Specificity of BUZ, PDZ, SH2, and Tandem BRCT Domains
Shimko Synthetic Tools for the Preparation of Modified Histones
CN110198951A (zh) 结合肽